PL377110A1 - Zapobieganie i leczenie choroby Alzheimera - Google Patents

Zapobieganie i leczenie choroby Alzheimera

Info

Publication number
PL377110A1
PL377110A1 PL377110A PL37711003A PL377110A1 PL 377110 A1 PL377110 A1 PL 377110A1 PL 377110 A PL377110 A PL 377110A PL 37711003 A PL37711003 A PL 37711003A PL 377110 A1 PL377110 A1 PL 377110A1
Authority
PL
Poland
Prior art keywords
alzheimer
disease
prevention
treatment
Prior art date
Application number
PL377110A
Other languages
English (en)
Polish (pl)
Inventor
Thierry Canton
Laurent Pradier
Jesus Benavides
Hubert Heuer
Hans-Ludwig Schaefer
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Publication of PL377110A1 publication Critical patent/PL377110A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
PL377110A 2002-12-12 2003-12-10 Zapobieganie i leczenie choroby Alzheimera PL377110A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0215722A FR2848452B1 (fr) 2002-12-12 2002-12-12 Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer

Publications (1)

Publication Number Publication Date
PL377110A1 true PL377110A1 (pl) 2006-01-23

Family

ID=32338722

Family Applications (1)

Application Number Title Priority Date Filing Date
PL377110A PL377110A1 (pl) 2002-12-12 2003-12-10 Zapobieganie i leczenie choroby Alzheimera

Country Status (22)

Country Link
EP (1) EP1572174A1 (es)
JP (1) JP2006514063A (es)
KR (1) KR20050084250A (es)
CN (1) CN1726016A (es)
AR (1) AR042354A1 (es)
AU (1) AU2003296802A1 (es)
BR (1) BR0317280A (es)
CA (1) CA2507945A1 (es)
CO (1) CO5700712A2 (es)
FR (1) FR2848452B1 (es)
HR (1) HRP20050534A2 (es)
MA (1) MA27500A1 (es)
MX (1) MXPA05005556A (es)
NO (1) NO20053341L (es)
NZ (1) NZ540496A (es)
PE (1) PE20040770A1 (es)
PL (1) PL377110A1 (es)
RS (1) RS20050420A (es)
RU (1) RU2005121909A (es)
TW (1) TW200503707A (es)
WO (1) WO2004062652A1 (es)
ZA (1) ZA200504656B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
ZA200603165B (en) 2003-11-03 2007-07-25 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
AU2005210004B2 (en) 2004-02-05 2010-10-28 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
WO2006050359A2 (en) 2004-11-02 2006-05-11 Northwestern University Pyridazine compounds and methods
EP2015750A2 (en) 2006-04-28 2009-01-21 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
EP2937085B1 (en) * 2007-05-22 2019-07-10 Otsuka Pharmaceutical Co., Ltd. A medicament comprising a carbostyril derivative and donezepil for treating alzheimer's disease
CN107375932B (zh) 2011-10-28 2021-12-21 夏尔人类遗传性治疗公司 用于治疗小儿胆汁淤积性肝病的胆汁酸再循环抑制剂
EA029581B1 (ru) * 2011-10-28 2018-04-30 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Применение ингибиторов рециркуляции желчных кислот для лечения холестатического заболевания печени или прурита

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2040996A1 (en) * 1990-05-02 1991-11-03 Robert L. Albright Composition and method for controlling cholesterol
CA2104594C (en) * 1991-02-22 2004-05-11 Howard K. Shapiro Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology
AU3585397A (en) * 1996-06-27 1998-01-14 G.D. Searle & Co. Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
US5985936A (en) * 1997-12-18 1999-11-16 Forbes Medi-Tech, Inc. Method of preventing and delaying onset of Alzheimer's disease and composition therefor
CA2311356C (en) * 1998-01-28 2004-07-13 Warner-Lambert Company Method for treating alzheimer's disease
US6080778A (en) * 1998-03-23 2000-06-27 Children's Medical Center Corporation Methods for decreasing beta amyloid protein
DE19825804C2 (de) * 1998-06-10 2000-08-24 Aventis Pharma Gmbh 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
WO2001056579A1 (en) * 2000-02-04 2001-08-09 Esperion Therapeutics Inc. Methods for treating alzheimer's disease
US20020028826A1 (en) * 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
SE0104334D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
TWI329111B (en) * 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents

Also Published As

Publication number Publication date
KR20050084250A (ko) 2005-08-26
CA2507945A1 (fr) 2004-07-29
CO5700712A2 (es) 2006-11-30
NO20053341L (no) 2005-09-07
NZ540496A (en) 2008-04-30
BR0317280A (pt) 2005-11-08
AU2003296802A1 (en) 2004-08-10
JP2006514063A (ja) 2006-04-27
ZA200504656B (en) 2006-08-30
RU2005121909A (ru) 2006-01-20
NO20053341D0 (no) 2005-07-08
PE20040770A1 (es) 2004-12-10
FR2848452B1 (fr) 2007-04-06
MXPA05005556A (es) 2005-07-26
RS20050420A (en) 2007-04-10
TW200503707A (en) 2005-02-01
EP1572174A1 (fr) 2005-09-14
MA27500A1 (fr) 2005-08-01
AR042354A1 (es) 2005-06-15
CN1726016A (zh) 2006-01-25
HRP20050534A2 (en) 2006-11-30
WO2004062652A1 (fr) 2004-07-29
FR2848452A1 (fr) 2004-06-18

Similar Documents

Publication Publication Date Title
AU2003290548A8 (en) Prevention and treatment of synucleinopathic disease
AU2003220096A8 (en) Methods for alzheimer's disease treatment and cognitive enhancement
AU2001249835A1 (en) Diagnosis and treatment of alzheimer's disease
IL149924A0 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
AU2003206413A8 (en) Substituted amino carboxamides for the treatment of alzheimer's disease
SI1303272T1 (sl) Derivati benzotiazola za zdravljenje alzheimerjeve bolezni in parkinsonove bolezni
EP1817050A4 (en) DIAGNOSIS AND TREATMENT OF MORBUS ALZHEIMER
AU2003231252A1 (en) Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease
AU2002335794A1 (en) Allylamides useful in the treatment of alzheimer's disease
AU2003268295A8 (en) "diagnosis and treatment of infertility"
NO20053341D0 (no) Hindring og behandling av Alzheimers sykdom.
AU2002222108A1 (en) Diagnosis and treatment of alzheimer's disease
AU2003303141A8 (en) Hydroxypropyl amides for the treatment of alzheimer's disease
IL160018A0 (en) Isoxazolopyridinones and use thereof in the treatment of parkinson's disease
AU2003248660A8 (en) Treatment of vascular dysfunction and alzheimer's disease
IL172213A0 (en) Compounds useful in the therapy of alzheimer's disease and formulations containing them
AU5550800A (en) Diagnosis and treatment of alzheimer's disease
AU2003231279A8 (en) Prevention and treatment of type 2 diabetes
AU2003228339A8 (en) Prevention and treatment of disease using angiogenesis-and/or tumor antigens
AU2003230848A8 (en) Methods and compositions for treating alzheimer's disease
AU2003286530A8 (en) Substituted peptides useful in the treatment of alzheimer's disease
AU2003245674A8 (en) Oral disease prevention and treatment
AU2002319451A1 (en) Therapeutic strategies for prevention and treatment of alzheimer's disease
EP1669085A4 (en) THERAPEUTIC AGENT FOR THE PREVENTION AND / OR TREATMENT OF ALZHEIMER'S DISEASE
GB0008162D0 (en) Diagnosis and treatment of alzheimer's disease

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)